Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues.

Aminoquinolines/therapeutic use; Antineoplastic Agents/therapeutic use; Carcinoma, Squamous Cell/diagnosis/drug therapy/pathology; Humans; Keratosis/diagnosis/drug therapy/etiology/pathology; Photochemotherapy; Precancerous Conditions/diagnosis/drug therapy/etiology/pathology; Receptor, Epidermal Growth Factor/antagonists & inhibitors; Skin Neoplasms/diagnosis/drug therapy/pathology; Sunlight/adverse effects

Abstract :

[en] Actinic keratoses (AKs) and their derived squamous cell carcinomas are distinctive lesions forming a continuum in a multi-step carcinogenesis process. They are typically found on chronically sun exposed skin. AKs merit to be recognized as such and to be distinguished from squamous cell carcinomas both conceptually and for therapeutic implications. The histological differences between these lesions are well defined and should not be blurred. A brief review is presented about the biological features responsible for AKs and the clinicopathologically distinctive aspects of these lesions. In addition, recent findings are presented about pharmacotherapy using anti-epidermal growth factor receptors, imidazoquinolines, diclofenac-hyaluronan, and methyl aminolevulinate photodynamic therapy.

Disciplines :

Dermatology

Author, co-author :

Quatresooz, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Pierard, Claudine ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Paquet, Philippe ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Hubert, Pascale ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Delvenne, Philippe ; Université de Liège - ULiège > Département des sciences biomédicales et précliniques > Anatomie et cytologie pathologiques

Pierard, Gérald ; Centre Hospitalier Universitaire de Liège - CHU > Dermatopathologie

Language :

English

Title :

Crossroads between actinic keratosis and squamous cell carcinoma, and novel pharmacological issues.

Publication date :

2008

Journal title :

European Journal of Dermatology

ISSN :

1167-1122

Publisher :

John Libbey Eurotext, Montrouge, France

Volume :

Issue :

Pages :

6-10

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 16 December 2008

Statistics

Number of views

175 (8 by ULiège)

Number of downloads

5 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Glogau R. The risk of progression to invasive disease. J Am Acad Dermatol 2000; 42: 23-4.
Person JR. An actinic keratosis is neither malignant nor premalignant: it is an initiated tumor. J Am Acad Dermatol 2003; 48: 637-8.
Smoller BR. Squamous cell carcinoma: from precursor lesions to high-risk variants. Mod Pathol 2006; 19: S88-S92.
Hurt MA. The nature of solar (actinic) keratosis. Br J Dermatol 2007; 156: 408-9.
Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). J Am Acad Dermatol 2000; 42: 11-7.
Ackerman AB. Actinic keratoses, malignant or not? J Am Acad Dermatol 2001; 45: 466-9.
Cockerell CJ. Pathology and pathobiology of actinic (solar) keratosis. Br J Dermatol 2003; 149: S34-S36.
Fu W, Cockerell CJ. The actinic (solar) keratosis: a 21 st-century perspective. Arch Dermatol 2003; 139: 66-70.
Ackerman AB, Mones JM. Solar (actinic) keratosis is squamous cell carcinoma. Br J Dermatol 2006; 155: 9-22.
Dodson JM, DeSpain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: a patient-oriented perspective. Arch Dermatol 1991; 127: 1029-31.
Wheeland RG. The pitfalls of treating all actinic keratoses as squamous cell carcinomas. Semin Cutan Med Surg 2005; 24: 152-4.
Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I- Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1302-7.
Mittelbronn MA, Mullins DL, Ramos-Caro FA, Flowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677-81.
Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in Merseyside population. Br J Dermatol 2000; 142: 1154-9.
Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: 4-7.
Uhoda I, Quatresooz P, Fumal I, Nikkels AF, Piérard-Franchimont C, Piérard GE. Updating trends in cutaneous cancers in south-east Belgium. Oncol Rep 2004; 12: 111-4.
Araki K, Nagano T, Ueda M, Washio F, Watanabe S, Yamaguchi N, et al. Incidence of skin cancers and precancerous lesions in Japanese-risk factors and prevention. J Epidemiol 1999; 9: S14-S21.
Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a Queensland community. J Invest Dermatol 2000; 115: 273-7.
Marks R, Rennie G, Selwood TS. The relationship of basal cell carcinomas and squamous cell carcinomas to solar keratoses. Arch Dermatol 1988; 124: 1039-42.
Carag HR, Prieto VG, Yballe LS, Shea CR. Utility of step sections: demonstration of additional pathological findings in biopsy samples initially diagnosed as actinic keratosis. Arch Dermatol 2000; 136: 471-5.
Anwar J, Wrone DA, Kimyai-Asdi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 2004; 22: 189-96.
Einspahr JG, Alberts DS, Warneke JA, Bozzo P, Basye J, Grogan TM, et al. Relationship of p53 mutation to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. Neoplasia 1999; 1: 468-75.
Mortier L, Marchetti P, Delaporte E, Martin de Lassalle E, Thomas P, et al. Progression of actinic keratosis to squamous cell carcinoma of the skin correlates with deletion of the 9p21 region encoding the p16 INK4a tumor suppressor. Cancer Lett 2002; 176: 205-14.
Filipowicz E, Adegboyega P, Sanchez RL, Gatalica Z. Expression of CD95 (Fas) in sun-exposed human skin and cutaneous carcinomas. Cancer 2002; 94: 814-9.
Ramzi ST, Maruno M, Khaskhely NM, Khan MA, Takamiyagi A, Uezato H, et al. An assessment of the malignant potential of actinic keratoses and Bowen's disease: p53 and PCNA expression pattern correlate with the number of desmosomes. J Dermatol 2002; 29: 562-72.
Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratoses revealed by comparative genomic hybridization. Arch Dermatol 2003; 139: 876-82.
Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. Cancer Res 2003; 63: 1727-30.
Uhoda I, Quatresooz P, Piérard-Franchimont C, Piérard GE. Nudging epidermal field cancerogenesis by imiquimod. Dermatology 2003; 206: 357-60.
Quatresooz P, Petit L, Uhoda I, Piérard-Franchimont C, Piérard GE. Mosaic subclinical melanoderma. An Achilles heel for UV-related epidermal carcinogenesis? Int J Oncol 2004; 25: 1763-7.
Matsumara Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV radiation of skin: implications for molecular medicine. Expert Rev Mol Med 2002; 2002: 1-22.
Paquet P, Piérard GE. Invasive atypical fibroxanthoma and eruptive actinic keratoses in a heart transplant patient. Dermatology 1996; 192: 411-3.
Euvrard S, Kanitakis J, Claudy A. Skin cancers in organ transplant recipients. N Engl J Med 2003; 348: 1681-91.
Tomas D, Kruslin B, Cupic H, Stanimirovic A, Bosnjak B, Lovricevic I, Belicza M. Correlation between Bcl-2 and Bax in atrophic and hypertrophic type of actinic keratosis. J Eur Acad Dermatol Venereol 2006; 20: 51-7.
Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. J Am Acad Dermatol 2000; 42: S8-S10.
Quaedvlieg PJF, Tirsi E, Thissen MRTM, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16: 335-9.
Berhane T, Halliday GM, Cooke B, Barnetson RS. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002; 146: 810-5.
Guenthner ST, Hurwitz RM, Buckle IJ, Gray HR. Cutaneous squamous cell carcinomas consistently show histologic evidence of in situ changes: A clinicopathologic correlation. J Am Acad Dermatol 1999; 41: 443-8.
Dinehart SM. The treatment of actinic keratoses. J Am Acad Dermatol 2000; 42: 525-8.
Jeffes WB, Tang EG. Actinic keratosis: current treatment options. Am J Clin Dermatol 2000; 1: 167-79.
Berman B, Villar AM, Ramirez CC. Mechanisms of action of new treatment modalities for actinic keratosis. J Drugs Dermatol 2006; 5: 167-73.
Gold MH, Nestor MS. Current treatments of actinic keratosis. J Drugs Dermatol 2006; 5: S17-S25.
Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599-606.
Lacouture ME, Desai A, Soltani K, Petronic-Rosic V, Laumann AE, Ratain MJ, et al. Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor. Clin Exp Dermatol 2006; 31: 783-5.
Hermanns JF, Piérard GE, Quatresooz P. Erlotinib-responsive actinic keratosis. Oncol Rep 2007; 18: 581-4.
Scurry J. Grading of actinic keratosis. J Am Acad Dermatol 2001; 44: 1052-3.
Epstein E. Quantifying actinic keratosis: assessing the evidence. Am J Clin Dermatol 2004; 5: 141-4.
Stanley MA. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. Clin Exp Dermatol 2002; 27: 571-7.
Sauder DN. Imiquimod: modes of action. Br J Dermatol 2003; 149: S5-S8.
Stockfleth E, Meyer T, Benninghoff B, Salasche S, Papadopoulos L, et al. A randomized, double-blind, vehicle-controlled study to assess 5% imiquimod cream for the treatment of multiple actinic keratoses. Arch Dermatol 2002; 138: 1498-502.
Schon MP, Schon M. Immune modulation and apoptosis induction: two sides of the antitumoral activity of imiquimod. Apoptosis 2004; 9: 291-8.
Stockfleth E, Christophers E, Benninghoff B, Sterry W. Low incidence of new actinic keratoses after topical 5% imiquimod cream treatment: a long-term follow-up study. Arch Dermatol 2004; 140: 1542.
Gupta AK, Davey V, Mcphail H. Evaluation of the effectiveness of imiquimod and 5-fluorouracil for the treatment of actinic keratosis: critical review and meta-analysis of efficacy studies. J Cutan Med Surg 2005; 9: 209-14.
Korman N, Moy R, Ling M, Matheson R, Smith S, McKane S, et al. Dosing with 5% imiquimod cream 3 times per week for the treatment of actinic keratosis: results of two phase 3, randomized, double-blind, parallel-group, vehicle-controlled trials. Arch Dermatol 2005; 141: 467-73.
Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: a meta-analysis of randomized controlled trials. J Am Acad Dermatol 2006; 55: 537-8.
Hadley G, Derry S, Moore RA. Imiquimod for actinic keratosis: systematic review and meta-analysis. J Invest Dermatol 2006; 126: 1251-5.
Ulrich C, Busch JO, Meyer T, Nindl I, Schmook T, Sterry W, et al. Successful treatment of multiple actinic keratoses in organ transplant patients with topical 5% imiquimod: a report of six cases. Br J Dermatol 2006; 155: 451-4.
Alomar A, Bichel J, McRae S. Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. Br J Dermatol 2007; 157: 133-41.
Jorizzo J, Dinehart S, Matheson R, Moore JK, Ling M, Fox TL, et al. Vehicle-controlled, double-blind, randomized study of imiquimod 5% cream applied 3 days per week in one or two courses of treatment for actinic keratoses on the head. J Am Acad Dermatol 2007; 57: 265-8.
Ben M'barek L, Mebazaa A, Euvrard S, et al. 5% topical imiquimod tolerance in transplant recipients. Dermatology 2007; 215: 130-3.
Gibson SJ, Lindh JM, Riter TR, et al. Plasmacytoid dendritic cells produce cytokines and mature in response to the TLR7 agonists, imiquimod and resiquimod. Cell Immunol 2002; 218: 74-86.
Quatresooz P, Piérard GE. Imiquimod-responsive basal cell carcinomas and factor XIIIa-enriched dendrocytes. Clin Exp Dermatol 2003; 28: S27-S29.
Schon M, Bong AB, Drewniok C, et al. Tumor-selective induction of apoptosis and the small-molecule immune response modifier imiquimod. J Natl Cancer Inst 2003; 95: 1138-49.
Wolf Jr. JE, Taylor JR, Tschen E, Kang S. Topical 3,0 % diclotenac in 2,5 % hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol 2001; 40: 709-13.
Adamson DJA, Frew D, Tatoud R, Wolf CR, Palmer CN. Diclofenac antagonizes peroxisome proliferators-activated receptor-γ signalling. Mol Pharmacol 2002; 61: 7-12.
Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Paulin Y. Topical treatment of actinic keratoses with 3.0 % diclofenac in 2, % hyaluronan gel. Br J Dermatol 2002; 146: 94-100.
Jarvis B, Figgit DP. Topical 3% diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol 2003; 4: 203-13.
Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3% diclofenac sodium topical gel (Solaraze™). J Drugs Dermatol 2004; 3: 401-7.
Pirard D, Vereecken P, Mélot C, Heenen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratosis: a meta-analysis of the recent studies. Arch Dermatol 2005; 297: 185-9.
Buckman SY, Gresham A, Hale P, Hruza G, Anast J, Masferrer J, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. Carcinogenesis 1998; 19: 723-9.
Pariser DM, Lowe NJ, Stewart DM, Jarrat MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate for actinic keratosis: results of a prospective randomized multicenter trial. J Am Acad Dermatol 2003; 48: 227-32.
Babilas P, Landthaler M, Szeimies RM. Photodynamic therapy in dermatology. Eur J Dermatol 2006; 16: 340-8.
Braathen LR, Szeimies RM, Basset-Seguin N, Bissonnette R, Foley P, Pariser D, et al. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. J Am Acad Dermatol 2007; 56: 125-43.
Siddiqui MAA, Perry CM, Scott LJ. Topical methyl aminolevulinate. Am J Clin Dermatol 2004; 5: 127-37.
Pariser DM, Lowe NJ, Stewart DM, Jarratt MT, Lucky AW, Pariser RJ, et al. Photodynamic therapy with topical methyl aminolevulinate (Metvix®) is effective and safe in the treatment of actinic keratosis: results of a prospective randomized trial. J Am Acad Dermatol 2003; 48: 227-32.
Szeimies RM, Karrer S, Radakovic-Fijan S, Tanew A, Calzavara-Pinto PG, Zane C, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: a prospective, randomized study. J Am Acad Dermatol 2002; 47: 258-62.
Freeman M, Vinciullo C, Francis D, Spelman L, Nguyen R, Fergin P, et al. A comparison of photodymic therapy using topical methyl aminolevulinate (Metvix®) with single cycle cryotherapy in patients with actinic keratosis: a prospective, randomized study. J Dermatol Treat 2003; 14: 99-106.